Recently, LRP1B mutation status was associated with improved patients’ outcome to immunotherapy, being described as a biomarker for ICIs in multiple cancers such as melanoma, non-small cell lung cancer, prostate cancer, and advanced biliary tract cancer [58,79,89,119]. The gene discussed is LRP1B; the disease is prostate carcinoma.